SEARCH

SEARCH BY CITATION

References

  • 1
    Annual Report of the US Scientific Registry for Organ Transplantation and the Organ Procurement and Transplantation Network—Transplant Data: 1988–1998. Transplant Recipients Characteristics, Table 22. UNOS, Richmond, VA, and the Department of Transplantation, Bureau of Health Resources and Services Administration, US Department of Health and Human Services, Rockville, MD, 1998.
  • 2
    Margolis HS, Alter MJ, Hadler SC. Hepatitis B: Evolving epidemiology and implications for control. Semin Liver Dis 1991; 11:8492. MEDLINE
  • 3
    Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991; 13:619626. MEDLINE
  • 4
    O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. Hepatology 1992; 14:104111.
  • 5
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329:18421847. MEDLINE
  • 6
    McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61:13581364. MEDLINE
  • 7
    Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamiduvine and HBIG. Hepatology 1998; 28:585589. MEDLINE
  • 8
    Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6:741748. MEDLINE
  • 9
    McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B replication in vitro. Hepatology 1995; 22:3643. MEDLINE
  • 10
    Tur-Kaspa R, Shaul Y, Moore DD, Burk RD, Okret S, Poellinger L, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988; 167:630633. MEDLINE
  • 11
    Lake JR, Wright TL. Liver transplantation for patients with hepatitis B: What have we learned from our results? Hepatology 1991; 13:796798. MEDLINE
  • 12
    Gish RG, Keeffe EB, Lim J, Brooks LJ, Esquivel CO. Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression. J Hepatol 1995; 22;257262. MEDLINE
  • 13
    Wright HI, Gavaler JS, Van Thiel DS. Preliminary experience with interferon therapy of viral hepatitis in liver allograft recipients. Transplantation 1992; 53:121124. MEDLINE
  • 14
    Terrault NA, Holland CC, Ferrell L, Hahn JA, Lake JR, Roberts JP, et al. Interferon alfa for recurrent hepatitis B after liver transplantation. Liver Transpl Surg 1996; 2:132138. MEDLINE
  • 15
    Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29:15811586. MEDLINE
  • 16
    Malkan G, Cattral MS, Humar A, Al Asghar H, Greig P, Hemming AW, et al. Lamivudine for hepatitis B in liver transplantation. Transplantation 2000; 69:14031407. MEDLINE
  • 17
    Chan T, Wu P, Li F, Lai C, Cheng P, Lai K. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology 1998; 115:177181. MEDLINE
  • 18
    Faraidy KA, Yoshida EM, Davis JE, Vartanian RK, Anderson FH, Steinbrecher UP. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 1997; 64:926928. MEDLINE
  • 19
    Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after liver transplantation. Lancet 1997; 349:2022. MEDLINE
  • 20
    Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and take over of YMDD motif mutant hepatitis B virus during long term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27:17111717. MEDLINE
  • 21
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711713. MEDLINE
  • 22
    Melagari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628633. MEDLINE
  • 23
    Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46:107113. MEDLINE
  • 24
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:3141. MEDLINE
  • 25
    Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999; 37:33383347. MEDLINE
  • 26
    Tillman HL, Bock TC, Locarnini SA, Torrest J, Jaeckel E, Rosnau J, et al. Risk factors for selection of YMDD mutants, their consequences in liver transplant recipients, ranging from sudden onset of liver failure to no disease [abstract]. Hepatology 2000; 32:376A.
  • 27
    Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28:16691673. MEDLINE
  • 28
    Perrillo R, Schiff ER, Yoshida E, Statler A, Hirsch K, Wright T, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32:129134. MEDLINE
  • 29
    Bartholomeusz A, Schnazi RF, Locarnini SA. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling disease. Viral Hepatitis Rev 1998; 4:167187.
  • 30
    Nevens F, de Man R, Chua D, Gadano A, Bies M, Thomas N, et al. Effectiveness of low dose of entecavir in treating recurrent viremia in chronic hepatitis B [abstract]. Hepatology 2000; 32:376A.
  • 31
    Nery JR, Weppler D, Rodriguez M, Ruiz P, Schif ER, Tzakis AG. Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 1998; 65:16151621. MEDLINE